Latest Headlines

Latest Headlines

Roche shops around for sequencing tech with Lumora buy

Roche has been hot on the trail of sequencing deals this past year, snatching up companies to build out its genomic analysis offerings. In its latest move, the company is buying sequencing products from molecular diagnostics firm Lumora to support its burgeoning portfolio.

UPDATED: Dumped by Roche, Constellation celebrates end of an option deal

Not very surprisingly, Roche's big biotech subsidiary Genentech is taking a pass on its option to buy out Constellation Pharmaceuticals.

China swings from weak sales outlook to savior on reforms?

China's decision this week to spur innovation and approvals in drugs and medical devices has allowed for some long-term silver lining prospects for European drug makers after disappointing second quarter sales for most multinational firms there, Reuters reports.

Roche's M&A party rages on with Kapa Biosystems deal

Roche has been hot on the dealmaking trail this past year, snatching up smaller companies to boost its portfolio. In its latest round of M&A, the diagnostics giant is acquiring Kapa Biosystems, getting its hands on the company's next-generation sequencing (NGS) products to further build out its offerings.

Roche makes another Dx acquisition of genomic reagent player Kapa

Sharpening its edge in diagnostics is core to the revenue growth strategy at Roche. The biopharma's deal activity in the last week is certainly a testament to that. It will acquire Kapa Biosystems, which provides enzyme optimization for next-gen sequencing and PCR.

Hunting fast OK in lung cancer, Roche racks up a positive PhII for 'atezo'

Roche is spotlighting another success for its PD-L1 checkpoint drug atezolizumab, with company execs applauding a positive finish in a big mid-stage study in non-small cell lung cancer. The news follows a string of steady pipeline advancements for a drug that has emerged as the pharma giant's biggest single late-stage blockbuster contender.

Roche rolls out smartphones for continuous monitoring of participants in Parkinson's trial

Roche is using smartphones to gather data on participants in a Parkinson's disease clinical trial between site visits. The devices will enable both active and passive data collection, with patients being asked to complete daily tests and smartphone sensors gathering information as they go about their lives.

Roche deploying smartphone app to monitor patients during clinical trial of its Parkinson's med

Big Pharma player Roche will use an internally developed smartphone app to monitor the progress of patients during a Phase I clinical trial of its Parkinson's candidates.

Roche dumps its cancer drug R&D pact with Wilex

Roche is bowing out of a two-year-old collaboration with a subsidiary of a struggling Wilex.

Wilex's stock tanks after Roche exits alliance to focus on immuno-oncology

Wilex has become one of the early losers of the immuno-oncology gold rush. The blow was dealt by Roche, which has axed its alliance with Wilex subsidiary Heidelberg Pharma as part of its retreat from areas of cancer R&D beyond immuno-oncology.